Expectations are high for combining human and artificial intelligence against health problems.
“Start by determining the problem you desire to solve, then decide on the technology to solve it,” said Subha Madhavan, vice president and head of clinical artificial intelligence/machine learning with global biopharmaceutical company Pfizer.
Madhavan was the keynote speaker at AI for Pediatric Health and Rare Diseases, an inter-institutional meeting of scientists and innovators co-led by Children’s National Hospital and the Virginia Tech Sanghani Center for Artificial Intelligence and Data Analytics to discuss the potential of artificial intelligence (AI) to understand pediatric health.
The pressing issue at the gathering at the Children’s National Research & Innovation Campus in Washington, D.C., involved tackling diseases, particularly cancer, in children, an area that suffers from limited treatment options and inadequate research compared with diseases affecting adults.
“It’s hard to think of a more compelling subject than using AI to advance children’s health,” said Madhavan, who was on the Pfizer team that developed the first Food and Drug Administration (FDA)-approved oral treatment for COVID-19. “Data insights powered by AI are key to the speed and innovation of medicine development and enhancing patient outcomes and experiences.”
Click here to read more via newsvt.edu